| abstract |
Herein methods are provided for determining the distribution of Rad51 foci in a first tissue type of a first individual, and then comparing the distribution to the distribution of Rad51 foci from a second normal tissue type from the first individual or a second unaffected individual. A difference in the distributions indicates that the first individual is at risk for a disease state which results in aberrant Rad51 foci. Preferred disease states include cancer and disease states associated with apoptosis. Also provided herein are methods for screening for modulators of Rad51 or homologues thereof and methods of using modulators of Rad51. |